Compare iShares International Treasury Bond ETF (IGOV) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Moderna, Inc. — how do they compare? iShares International Treasury Bond ETF trades at $41.25, while Moderna, Inc. trades at $63.7 (market cap $24.18B). The key difference: Moderna, Inc. is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IGOV | MRNA | |
|---|---|---|
52-Week High | $43.09 | $81.80 |
52-Week Low | $40.35 | $22.36 |
Market Cap | — | $24.18B |
Sector | — | Health |
Enterprise Value | — | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV, an iShares International Treasury Bond ETF trading as a US stock, is priced at $41.19 with no recent change. Technical indicators show a bullish trend from moving averages, while oscillators are neutral. The asset faces pressure from global inflationary trends and rising interest rates, as highlighted in recent financial news.
The outlook for IGOV is cautious due to its high duration exposure amplifying risks from global rate hikes. Investment opportunities are limited by macroeconomic headwinds, with key risks including capital loss potential from prolonged energy issues and geopolitical tensions affecting international bond markets.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
